Jong Seo LEE,Kyu Tae KIM,Bong Kook KO,Ki Hyun KIM,Hyun Jong LEE
申请号：
US15780046
公开号：
US20190241666A1
申请日:
2016.11.25
申请国别(地区):
US
年份:
2019
代理人:
摘要：
A novel antibody against VEGFR2 for use in the prevention or treatment of macular degeneration and cancer, which are angiogenesis-related diseases. The antibody of the present invention is an antibody which specifically binds to VEGFR2 which is overexpressed in vascular endothelial cells. The antibody of the present invention has very low homology compared to the CDR sequences of conventional VEGFR2 target antibodies, and thus is unique in its sequence. Since the antibody of the present invention, when treated alone, has the ability to inhibit vascular endothelial cell growth equivalent to that of ramucirumab which is conventionally used, it is very effective to prevent or treat angiogenesis-related diseases.
